MENS NASDAQ
Jyong Biotech Ltd. Ordinary Shares
1W: +0.0%
1M: -8.8%
3M: +3.5%
YTD: -39.0%
$2.15
+0.07 (+3.37%)
Weekly Expected Move ±8.5%
$2
$2
$2
$2
$2
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Smart Money Score
Watch
0
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$163.5M
52W Range1.43-67
Volume44,474
Avg Volume166,528
Beta2.62
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOFu-Feng Kuo
Employees31
SectorHealthcare
IndustryBiotechnology
IPO Date2025-06-17
Websitejyongbio.com/
23Fâ3, No.â¯95, Section 1, Xintai 5th Road
New Taipei City 221
TW
New Taipei City 221
TW
886 2 2732 5205
About Jyong Biotech Ltd. Ordinary Shares
Jyong Biotech Ltd. is a Taiwan-based biotech firm focused on developing and commercializing plant-derived drugs targeting urinary system diseases. The company operates through its subsidiariesâHealth Ever Bio-Tech, Genvace, and othersâworking on drug candidates like MCSâ2 (for BPH) currently in Phase III, PCP (for prostate cancer) in Phase II, and IC in pre-clinical stages
Latest News
Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025
Jyong Biotech Responds to Share Price and Volume Movement
Jyong Biotech Ltd.’s (NASDAQ:MENS) Lock-Up Period Will End on December 15th
Jyong Biotech Expands Regional Partnerships, Signs MOU with a Vietnam Pharmaceutical Distributor for MCS‑2 Market Entry
Recent Insider Trades
No insider trades found